⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234698 | 1.00 | — | — | |
| SCHEMBL9701444 | 0.69 | — | — | |
| SCHEMBL1479375 | 0.67 | — | — | |
| SCHEMBL7856417 | 0.62 | — | — | |
| SCHEMBL16757447 | 0.62 | NISCH (0.43) | — | |
| SCHEMBL16496273 | 0.62 | — | — | |
| SCHEMBL940795 | 0.62 | — | — | |
| SCHEMBL1001194 | 0.60 | MAPT (0.33) | — | |
| SCHEMBL7854023 | 0.58 | NISCH (0.41) | — | |
| SCHEMBL7854306 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258703-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7205316-B2 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1751130-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113536-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |